Peregrine Capital Management LLC increased its holdings in shares of TESARO, Inc. (NASDAQ:TSRO) by 18.9% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 118,090 shares of the biopharmaceutical company’s stock after acquiring an additional 18,743 shares during the quarter. Peregrine Capital Management LLC owned approximately 0.22% of TESARO worth $15,245,000 as of its most recent SEC filing.
Other institutional investors have also modified their holdings of the company. Tobam bought a new stake in TESARO during the second quarter worth $20,189,000. Sphera Funds Management LTD. bought a new stake in TESARO during the second quarter worth $7,692,000. Trellus Management Company LLC lifted its holdings in TESARO by 12.3% during the second quarter. Trellus Management Company LLC now owns 8,419 shares of the biopharmaceutical company’s stock worth $1,177,000 after acquiring an additional 919 shares during the period. Fiera Capital Corp bought a new stake in TESARO during the second quarter worth $18,451,000. Finally, Westpac Banking Corp bought a new stake in TESARO during the second quarter worth $599,000.
TSRO has been the topic of a number of recent analyst reports. Gabelli initiated coverage on TESARO in a report on Friday, July 7th. They set a “buy” rating and a $175.00 price target on the stock. Janney Montgomery Scott reiterated a “neutral” rating on shares of TESARO in a report on Friday, July 14th. ValuEngine lowered TESARO from a “hold” rating to a “sell” rating in a report on Monday, July 17th. BidaskClub lowered TESARO from a “sell” rating to a “strong sell” rating in a report on Wednesday, July 19th. Finally, Credit Suisse Group set a $198.00 price target on TESARO and gave the stock a “buy” rating in a report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $166.10.
In related news, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $135.00, for a total value of $1,912,545.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $117.13, for a total value of $1,171,300.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 35,692 shares of company stock worth $4,628,976. 34.60% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: “TESARO, Inc. (TSRO) Position Increased by Peregrine Capital Management LLC” was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2017/11/01/tesaro-inc-tsro-position-increased-by-peregrine-capital-management-llc.html.
TESARO, Inc. (TSRO) opened at 115.77 on Wednesday. TESARO, Inc. has a 12 month low of $106.64 and a 12 month high of $192.94. The stock’s market capitalization is $6.27 billion. The stock has a 50 day moving average price of $118.46 and a 200 day moving average price of $131.15.
TESARO (NASDAQ:TSRO) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.52) by ($0.30). TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The company had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. During the same period in the prior year, the business posted ($1.28) earnings per share. TESARO’s revenue for the quarter was down 17.6% compared to the same quarter last year. On average, equities research analysts forecast that TESARO, Inc. will post ($8.65) earnings per share for the current fiscal year.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
What are top analysts saying about TESARO Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc. and related companies.